NYC
We are investors, scientists, journalists and other thought leaders who gather to chat about NYC and DNA related sciences. The White House took to calling it The New Bioeconomy, and it will impact medicine, agriculture, chemicals, and bioindustrials. For fun, we call ourselves the Bioeconomy Supper Club. So, what better website than one designed like a restaurant? Enjoy the site, and like all good food, take it with a grain of salt. The Bioeconomy Supper Club is by invitation only. If you would like to be invited, just shoot us an email and tell us why. Contact spencer at spenceradler dot com.
NYC
We are investors, scientists, journalists and other thought leaders who gather to chat about NYC and DNA related sciences. The White House took to calling it The New Bioeconomy, and it will impact medicine, agriculture, chemicals, and bioindustrials. For fun, we call ourselves the Bioeconomy Supper Club. So, what better website than one designed like a restaurant? Enjoy the site, and like all good food, take it with a grain of salt. The Bioeconomy Supper Club is by invitation only. If you would like to be invited, just shoot us an email and tell us why. Contact spencer at spenceradler dot com.
The Destination
In the evolution of the computer industry, Moore's Law predicted exponential growth - a doubling of computer power per dollar every 18 months. Now the same growth is happening with DNA sequencing, editing, and synthesis.
The benefits of these exponential advances are now impacting our understanding of the cellular mechanisms that underpin many of the most devastating degenerative conditions.
Fascinating people are doing fascinating work. We enjoy bringing some of them together.
Why New York?
With the opening of the NY Genome Center in Soho in September of 2013 - slated to be the largest sequencing center in the United States - NYC staked a claim to the future of sequencing. Backed by MIchael Bloomberg, Jim Simons, and all 11 of the NYC area teaching hospitals, NYGC was part of a wave of new activity in advanced biology in NYC. In fact, the NYGC was the site of our very first Supper Club - less than a week after the NYGC’s ribbon cutting.
What's It All About?
We're a community with a spirit of friendship and cooperation. All of us are excited about the potential of new technologies to create profound and positive changes for both our society and for NYC.
What It's Not About
The Bioeconomy Supper Club is not about getting pitched, and it's not about cheerleading. Skepticism is especially welcome. That said, we aim to create evenings that are largely free of scientific jargon.
Eat Together
Good things happen when good people eat together.
Eat Together
Good things happen when good people eat together.
Think drinks and live jazz with an unexpected mix of fascinating people. Think a few thought-provoking five minute talks, with no powerpoints allowed. The industry we're building is a marathon - not a sprint. And we've hardly crossed the starting line. Let's enjoy the run together.
Dinner is paid for by a grant. If you'd like to contribute towards future suppers, be in touch about it.
Our Past Speakers
Our Past Speakers
TED
GENOMICS
Jimmy Lin is an MD PhD who, while at Hopkins, was the lead computational biologist on the team that sequenced the first cancer exomes. He is also the founder of a nonprofit crowdfunding platform for children with rare diseases that has over 30 partner and supporting organizations around the world (Rare Genomics). Jimmy understands the power of genomics to give hope to the hopeless. He is a TED fellow and was responsible for establishing the tumor sequencing program at NIH.
AUTODESK
DNA AS SOFTWARE
The publicly traded company Autodesk creates the CAD software used to make just about everything we can see and touch - buildings, consumer products, you name it. Autodesk's Distinguished Research Fellow is tasked with assisting Autodesk in now creating the software that will allow us to design the things we cannot see or feel - things built out of DNA and nanoparticles.
RBC
PUBLIC COMPANIES
The senior life sciences portfolio manager at one of the world's ten largest banks understands the publicly available investment opportunities in this space - with a special focus on sequencing companies (Illumina, Life/Thermo-Fisher, etc), and the recent IPO of Intrexon - the synthetic biology company now worth $2.4B. More companies are coming - from startups to IPOs.